TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06623409: A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540B in Healthy Adults.

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 124 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT06623409 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06623409 Rescue Dossier →